Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Dequalinium Chloride (Fluomizin) vs Oral Metronidazole for the Treatment of Bacterial Vaginosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Premenopausal woman ≥18 years~2. Diagnosis of bacterial vaginosis (all 4 Amsel criteria positive, i.e. 1) greyish white thin discharge, 2) postassium hydroxide (KOH) test or 'fishy' smell, 3) microscopic presence of \> 20% clue cells, 4) vaginal pH \> 4.5)~3. Signed Written Informed Consent to participate in this study~Exclusion Criteria:~1. Pregnancy and/or lactation based on urine Pregnancy test (women with childbearing potential should use any contraception excluding vaginal methods like vaginal ring, etc.)~2. Uterine bleeding (including menstruation) or vaginal bleeding of unknown origin~3. Ulcerations/erosions of vaginal mucosa or cervix uteri~4. Patients with clinical symptoms and findings of Candida vulvovaginitis and/or Aerobic vaginitis~5. Clinically manifest or suspicion of sexually transmitted infections (Neisseria gonorrhoeae, Chlamydia trachomatis, or Trichomonas vaginalis) based on signs, symptoms, and anamnesis~6. Use of any antimicrobial treatment (local or systemic) 14 days before entry the study~7. Use of any vaginal medication or vaginal douching 7 days before entry the study~8. Unwillingness to refrain from alcohol consumption during treatment, and 48 hours after treatment~9. Severe systemic diseases (HIV, cancer, tuberculosis, autoimmune diseases, diabetes mellitus, severe psychiatric conditions, etc.), including diseases treated with immunosuppressive therapies, systemic corticosteroids, or warfarin~10. Known or suspected hypersensitivity to one of the study medications, inclusive of their excipients~11. Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant (including inability to fill-in electronic patient diary)~12. Participation of patient in another investigational drug study concomitantly or within 30 days prior to entry in the study~13. Patient is relative of, or staff directly reporting to, the investigator

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dequalinium chloride (Type: EXPERIMENTAL): Dequalinium chloride 10 mg vaginal tablets
- Metronidazole (Type: ACTIVE_COMPARATOR): Metronidazole 500 mg oral tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).